JSPR (Jasper Therapeutics) Total Liabilities: $17.78 Mil (As of Mar. 2026)


JSPR Jasper Therapeutics Inc JSPR
24 GF Score
Price $0.43
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics Total Liabilities?

Jasper Therapeutics JSPR -5.19% 24 Total Liabilities is $17.78 Mil as of Mar. 2026. GuruFocus rates JSPR with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Jasper Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $17.78 Mil.

Jasper Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($45.90 Mil) to Dec. 2025 ($31.63 Mil) and declined from Dec. 2025 ($31.63 Mil) to Mar. 2026 ($17.78 Mil).

Jasper Therapeutics's annual Total Liabilities increased from Dec. 2023 ($16.45 Mil) to Dec. 2024 ($18.23 Mil) and increased from Dec. 2024 ($18.23 Mil) to Dec. 2025 ($31.63 Mil).

Jasper Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Jasper Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jasper Therapeutics Total Liabilities Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 24.14 12.37 16.45 18.23 31.63

Jasper Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.35 22.97 45.90 31.63 17.78
JSPR
24GF Score
Jasper Therapeutics Inc JSPR
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jasper Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Jasper Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.2+(0+18.428
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=31.63

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=35.779-4.151
=31.63

Jasper Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.996+(0+8.788
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=17.78

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=21.184-3.4
=17.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $17.78 Mil mean?
Jasper Therapeutics (JSPR) has a Total Liabilities of $17.78 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Jasper Therapeutics and its competitors.
Is Jasper Therapeutics' Total Liabilities too high?
Jasper Therapeutics' current Total Liabilities is $17.78 Mil. Overall, Jasper Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' Total Liabilities compare to CVKD and BRTX?
Jasper Therapeutics' Total Liabilities of $17.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Jasper Therapeutics and its competitors. Jasper Therapeutics's current Total Liabilities is $17.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current Total Liabilities of $17.78 Mil. The current Total Liabilities is $17.78 Mil. Jasper Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current Total Liabilities is $17.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
24GF Score

Get the complete analysis for JSPR

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price